Pith. sign in

REVIEW 2 major objections 72 references

ILLUME+ is a post-hoc framework that generates multi-form explanations for AI models predicting cancer drug responses from gene profiles, going beyond single-gene scores.

Reviewed by Pith at T0; open to challenge. T0 means a machine referee read the full paper against a public rubric. the ladder, T0–T4 →

Challenge this review Re-run · record.json Download PDF Read on arXiv ↗

T0 review · grok-4.3

2026-07-02 15:39 UTC pith:BOPOAMZW

load-bearing objection ILLUME+ claims multi-form post-hoc explanations for cancer drug response models that are more stable and recover known biology better than univariate attributions, but the abstract supplies zero methods or validation to support any of it. the 2 major comments →

arxiv 2607.00931 v1 pith:BOPOAMZW submitted 2026-07-01 cs.LG

Explainable AI for Cancer Drug Response Prediction: Beyond Univariate Feature Attributions

Martino Ciaperoni , Margherita Lalli , Simone Piaggesi , Martina Varisco , Francesco Carli , Riccardo Guidotti , Dino Pedreschi , Francesco Raimondi
show 1 more author
Fosca Giannotti
This is my paper
classification cs.LG
keywords explainable AIcancer drug responsetranscriptomic profilespost-hoc explanationsgene interactionsprecision oncologymachine learning interpretability
verification ladder T0 review T1 audit T2 compute T3 formal T4 reserved

The pith

A machine-rendered reading of the paper's core claim, the machinery that carries it, and where it could break.

The paper introduces ILLUME+, a scalable explainability method for machine learning models that predict how cancers respond to drugs using transcriptomic data. It argues that existing approaches are limited by high computational cost, instability, and a focus only on individual gene contributions while ignoring coordinated gene activity. ILLUME+ integrates multiple complementary explanation types into the prediction pipeline. This produces gene importance scores that hold up better across runs, align with established drug-gene links and drug mechanisms, and support generating new hypotheses about interaction-based molecular signals. A sympathetic reader would see value in turning accurate but opaque predictions into tools for biological discovery in precision oncology.

Core claim

ILLUME+ is a scalable post-hoc explainability framework that moves beyond single-gene assessments to capture multiple, complementary forms of explanation. Integrated into an end-to-end pipeline for cancer drug response prediction from transcriptomic profiles, it produces more stable gene importance scores than existing baselines, recovers established drug-gene associations and mechanisms of action, and enables AI-assisted hypothesis generation to uncover novel interaction-driven molecular signals in cancer biology.

What carries the argument

ILLUME+, the post-hoc explainability framework that integrates multiple complementary explanation types to capture coordinated gene activity rather than univariate attributions.

Load-bearing premise

The post-hoc explanations generated by ILLUME+ accurately capture coordinated biological mechanisms rather than model-specific artifacts or data biases.

What would settle it

Re-running ILLUME+ on the same trained models and data yields gene importance scores that vary substantially across trials, or the recovered associations fail to match independently verified drug-gene relationships from the literature.

Watch this falsifier — get emailed when new claim-graph text bears on it.

If this is right

  • Gene importance scores remain consistent when models are retrained or data splits change.
  • Explanations recover known drug targets and mechanisms of action documented in cancer biology.
  • AI outputs can be used to propose new hypotheses about gene interaction effects on drug sensitivity.
  • The framework scales to large transcriptomic datasets without the computational limits of prior methods.

Where Pith is reading between the lines

These are editorial extensions of the paper, not claims the author makes directly.

  • The same multi-explanation approach could transfer to other high-dimensional biological tasks such as predicting protein interactions or disease subtypes.
  • If the novel signals hold up in follow-up experiments, the method could shorten the cycle from computational prediction to lab validation of drug mechanisms.
  • Comparing ILLUME+ outputs against purely statistical gene correlation methods would clarify how much the AI model itself adds beyond data patterns.

Editorial analysis

A structured set of objections, weighed in public.

Desk editor's note, referee report, simulated authors' rebuttal, and a circularity audit.

Referee Report

2 major / 0 minor

Summary. The paper introduces ILLUME+, a scalable post-hoc explainability framework integrated into an end-to-end pipeline for predicting cancer drug response from transcriptomic profiles. It claims to move beyond univariate gene importance by capturing multiple complementary explanations, yielding more stable gene importance scores than baselines, recovering known drug-gene associations and mechanisms of action, and supporting AI-assisted hypothesis generation for novel interaction-driven molecular signals.

Significance. If the empirical claims are substantiated, the framework could meaningfully advance XAI applications in precision oncology by addressing limitations of current methods (computational cost, lack of robustness, and reduction to single-gene scores) and enabling more reliable extraction of coordinated biological insights from ML models.

major comments (2)
  1. [Abstract] Abstract: The abstract makes specific performance claims (more stable gene importance scores, recovery of established associations, enabling novel signal discovery) but provides no description of methods, datasets, baselines, stability metrics, validation procedures, or experimental design. Without these details the central claims cannot be evaluated for support.
  2. [Abstract] Abstract: No evidence or tests are supplied to address the risk that the generated explanations reflect model artifacts or data biases rather than coordinated biological mechanisms, leaving the claim of biological fidelity unsupported by the supplied text.

Simulated Author's Rebuttal

2 responses · 0 unresolved

We thank the referee for their comments. We address the two major points on the abstract below, noting that the full manuscript provides the supporting details while agreeing that the abstract could be strengthened for standalone clarity.

read point-by-point responses

  1. Referee: [Abstract] Abstract: The abstract makes specific performance claims (more stable gene importance scores, recovery of established associations, enabling novel signal discovery) but provides no description of methods, datasets, baselines, stability metrics, validation procedures, or experimental design. Without these details the central claims cannot be evaluated for support.

    Authors: We agree the abstract is high-level and omits these specifics due to length constraints. The Methods section details the end-to-end pipeline, datasets (GDSC, CCLE, TCGA), baselines (SHAP, LIME, Integrated Gradients), stability metrics (e.g., Jaccard consistency across bootstrap runs and perturbations), and experimental design (cross-validation, known association recovery). We will revise the abstract to briefly reference the key datasets, baselines, and stability evaluation approach. revision: yes

  2. Referee: [Abstract] Abstract: No evidence or tests are supplied to address the risk that the generated explanations reflect model artifacts or data biases rather than coordinated biological mechanisms, leaving the claim of biological fidelity unsupported by the supplied text.

    Authors: The abstract summarizes the claims, but the full manuscript supports biological fidelity through recovery of established drug-gene associations and mechanisms of action (detailed in Results), plus stability comparisons. We acknowledge that explicit controls for artifacts (e.g., permutation baselines or bias audits) are not highlighted in the abstract. We will add a short discussion of these controls in the revised manuscript's Discussion section. revision: partial

Circularity Check

0 steps flagged

No derivation chain or equations present; no circularity identified

full rationale

The manuscript abstract and context describe an empirical XAI framework (ILLUME+) for post-hoc explanations in cancer drug response models. No equations, derivations, fitted parameters presented as predictions, or self-citation load-bearing uniqueness theorems appear in the supplied text. Claims rest on stability metrics, recovery of known associations, and hypothesis generation, which are externally falsifiable via experiments rather than reducing to self-definition or input renaming. The derivation chain is therefore self-contained with no detectable circular steps.

Axiom & Free-Parameter Ledger

0 free parameters · 0 axioms · 0 invented entities

Abstract-only review yields no visible free parameters, axioms, or invented entities; all fields left empty.

pith-pipeline@v0.9.1-grok · 5692 in / 947 out tokens · 17836 ms · 2026-07-02T15:39:07.288232+00:00 · methodology

0 comments
read the original abstract

Predicting cancer drug response from transcriptomic profiles is a cornerstone of precision oncology, yet the scientific value of machine learning models hinges not solely on predictive accuracy, but also on their capacity to generate reliable biological insights. Current explainability approaches in this setting are computationally costly, lack robustness, and reduce complex drug response to univariate gene importance scores, overlooking the coordinated gene activity that drives sensitivity and resistance. In this work, we present ILLUME+, a scalable post-hoc explainability framework that moves beyond single-gene assessments to capture multiple, complementary forms of explanation. Integrated into our end-to-end pipeline, ILLUME+ produces more stable gene importance scores than existing baselines, recovers established drug-gene associations and mechanisms of action, and enables AI-assisted hypothesis generation to uncover novel interaction-driven molecular signals in cancer biology.

Figures

Figures reproduced from arXiv: 2607.00931 by Dino Pedreschi, Fosca Giannotti, Francesco Carli, Francesco Raimondi, Margherita Lalli, Martina Varisco, Martino Ciaperoni, Riccardo Guidotti, Simone Piaggesi.

Figure 1
Figure 1. Figure 1: Example gene graph for Venetoclax-sensitive cell lines. Strongly interacting genes identified by our approach are in red, neighboring genes from the STRING database in grey. Solid edges indicate high-confidence interactions from STRING, dashed links are inferred by our approach. More fundamentally, univariate explanations assess genes indepen￾dently, whereas cellular response to treatment arises from coor￾… view at source ↗
Figure 2
Figure 2. Figure 2: (a) ILLUME+ extends ILLUME through a 1-layer low-rank hypernetwork and a stochastic Jacobian penalty, improving [PITH_FULL_IMAGE:figures/full_fig_p004_2.png] view at source ↗
Figure 3
Figure 3. Figure 3: Putative gene recovery (measured via NDCG@k) [PITH_FULL_IMAGE:figures/full_fig_p006_3.png] view at source ↗
Figure 5
Figure 5. Figure 5: Robustness (measured via cosine similarity) across [PITH_FULL_IMAGE:figures/full_fig_p006_5.png] view at source ↗
Figure 6
Figure 6. Figure 6: Pathway-colored top-20 gene importance profiles for three example drugs for the resistant class. Genes associated [PITH_FULL_IMAGE:figures/full_fig_p007_6.png] view at source ↗
Figure 7
Figure 7. Figure 7: Examples of factual (top) and counterfactual (bot [PITH_FULL_IMAGE:figures/full_fig_p007_7.png] view at source ↗
Figure 8
Figure 8. Figure 8: Distribution of pathway overlap across drugs for the top (left box plot) and bottom (right box plot) 1,000 ranked pairs. [PITH_FULL_IMAGE:figures/full_fig_p008_8.png] view at source ↗
Figure 9
Figure 9. Figure 9: Pathway overlap for the top-20 gene pairs in [PITH_FULL_IMAGE:figures/full_fig_p008_9.png] view at source ↗
Figure 10
Figure 10. Figure 10: Empirical p-values for centrality measures of the [PITH_FULL_IMAGE:figures/full_fig_p009_10.png] view at source ↗
Figure 11
Figure 11. Figure 11: Null distribution of conductance and empirical [PITH_FULL_IMAGE:figures/full_fig_p009_11.png] view at source ↗

discussion (0)

Sign in with ORCID, Apple, or X to comment. Anyone can read and Pith papers without signing in.

Reference graph

Works this paper leans on

72 extracted references · 72 canonical work pages

  1. [1]

    2015.Foundations of linear and generalized linear models

    Alan Agresti. 2015.Foundations of linear and generalized linear models. John Wiley & Sons

    work page 2015

  2. [2]

    Takuya Akiba et al. 2019. Optuna: A next-generation hyperparameter optimiza- tion framework. InACM SIGKDD international conference on knowledge discovery & data mining. 2623–2631

    work page 2019

  3. [3]

    Aoula Al-Zebeeby et al. 2018. Targeting intermediary metabolism enhances the efficacy of BH3 mimetic therapy in hematologic malignancies.Haematologica 104, 5 (2018), 1016

    work page 2018

  4. [4]

    Jordi Barretina et al. 2012. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.Nature483, 7391 (2012), 603–607

    work page 2012

  5. [5]

    H Can Barutcu et al. 2025. Explainable artificial intelligence-based approaches for climate change: a review.International Journal of Global Warming35, 2-4 (2025), 244–260

    work page 2025

  6. [6]

    Iwona Bednarz-Misa et al. 2020. Interleukins 4 and 13 and their receptors are differently expressed in gastrointestinal tract cancers, depending on the anatomi- cal site and disease advancement, and improve colon cancer cell viability and motility.Cancers12, 6 (2020), 1463

    work page 2020

  7. [7]

    Elisabetta Botti et al. 2011. Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas.Proceedings of the National Academy of Sciences108, 33 (2011), 13710–13715

    work page 2011

  8. [8]

    Leo Breiman. 2001. Random Forests.Mach. Learn.45, 1 (2001), 5–32

    work page 2001

  9. [9]

    Aishwarya Budhkar et al. 2025. Demystifying the black box: A survey on explain- able artificial intelligence (XAI) in bioinformatics.Computational and Structural Biotechnology Journal(2025)

    work page 2025

  10. [10]

    Francesco Carli et al. 2025. Learning and actioning general principles of cancer cell drug sensitivity. 16, 1 (2025), 1654

    work page 2025

  11. [11]

    Jinyu Chen and Louxin Zhang. 2021. A survey and systematic assessment of computational methods for drug response prediction.Briefings in bioinformatics 22, 1 (2021), 232–246

    work page 2021

  12. [12]

    Steven M Corsello et al . 2020. Discovering the anticancer potential of non- oncology drugs by systematic viability profiling.Nature cancer1, 2 (2020), 235–248

    work page 2020

  13. [13]

    Beatriz Costa and Petia Georgieva. 2023. Explainable Artificial Intelligence in Healthcare Applications: A Systematic Review. In2023 International Scientific Conference on Computer Science (COMSCI). 1–8

    work page 2023

  14. [14]

    Liyuan Cui et al. 2024. GIMAP7 inhibits epithelial-mesenchymal transition and glycolysis in lung adenocarcinoma cells via regulating the Smo/AMPK signaling pathway.Thoracic Cancer15, 4 (2024), 286–298

    work page 2024

  15. [15]

    Janez Demsar. 2006. Statistical Comparisons of Classifiers over Multiple Data Sets.J. Mach. Learn. Res.7 (2006), 1–30

    work page 2006

  16. [16]

    Sarah C DiDonna et al. 2023. P4HTM: a novel downstream target of GATA3 in breast cancer.Research Square(2023), rs–3

    work page 2023

  17. [17]

    Linton C Freeman. 1978. Centrality in social networks conceptual clarification. Social networks1, 3 (1978), 215–239

    work page 1978

  18. [18]

    Judyta Gorka et al . 2021. MCPIP1 inhibits Wnt/ 𝛽-catenin signaling pathway activity and modulates epithelial-mesenchymal transition during clear cell renal cell carcinoma progression by targeting miRNAs.Oncogene40, 50 (2021), 6720– 6735

    work page 2021

  19. [19]

    Riccardo Guidotti et al . 2018. A survey of methods for explaining black box models.ACM computing surveys51, 5 (2018), 1–42

    work page 2018

  20. [20]

    Riccardo Guidotti et al. 2024. Stable and actionable explanations of black-box models through factual and counterfactual rules.Data Min. Knowl. Discov.38, 5 (2024), 2825–2862

    work page 2024

  21. [21]

    David Ha et al. 2017. HyperNetworks. InICLR (Poster). OpenReview.net

    work page 2017

  22. [22]

    Judy Hoffman et al. 2019. Robust Learning with Jacobian Regularization.CoRR abs/1908.02729 (2019)

    work page Pith review arXiv 2019

  23. [23]

    Noah Hollmann, Samuel Müller, Lennart Purucker, Arjun Krishnakumar, Max Körfer, Shi Bin Hoo, Robin Tibor Schirrmeister, and Frank Hutter. 2025. Accurate predictions on small data with a tabular foundation model.Nat.637, 8044 (2025), 319–326

    work page 2025

  24. [24]

    Wen Hwang et al. 2017. Expression of neuroendocrine factor VGF in lung cancer cells confers resistance to EGFR kinase inhibitors and triggers epithelial-to- mesenchymal transition.Cancer research77, 11 (2017), 3013–3026

    work page 2017

  25. [25]

    Francesco Iorio et al. 2016. A landscape of pharmacogenomic interactions in cancer.Cell166, 3 (2016), 740–754

    work page 2016

  26. [26]

    Janizek et al

    Joseph D. Janizek et al. 2023. Uncovering expression signatures of synergistic drug responses via ensembles of explainable machine-learning models.Nature Biomedical Engineering7, 6 (2023), 811–829

    work page 2023

  27. [27]

    Kalervo Järvelin and Jaana Kekäläinen. 2002. Cumulated gain-based evaluation of IR techniques.ACM Transactions on Information Systems20, 4 (2002), 422–446

    work page 2002

  28. [28]

    Tasnuva D Kabir et al. 2025. Inhibition of the Caveolin-1 pathway promotes apop- tosis and overcomes pan-tyrosine kinase inhibitor resistance in hepatocellular carcinoma.Cell Death & Disease16, 1 (2025), 561

    work page 2025

  29. [29]

    Guolin Ke et al. 2017. LightGBM: A Highly Efficient Gradient Boosting Decision Tree. InNIPS. 3146–3154

    work page 2017

  30. [30]

    Philip Keyl et al. 2025. Neural interaction explainable AI predicts drug response across cancers.NAR cancer7, 3 (2025), zcaf029

    work page 2025

  31. [31]

    Simon Kind et al. 2024. KLK7 expression in human tumors: a tissue microarray study on 13,447 tumors.BMC cancer24, 1 (2024), 794

    work page 2024

  32. [32]

    Brent M Kuenzi et al. 2020. Predicting drug response and synergy using a deep learning model of human cancer cells.Cancer cell38, 5 (2020), 672–684

    work page 2020

  33. [33]

    Ritika Kundra et al. 2021. OncoTree: a cancer classification system for precision oncology.JCO clinical cancer informatics5 (2021), 221–230

    work page 2021

  34. [34]

    Miron B Kursa and Witold R Rudnicki. 2010. Feature selection with the Boruta package.Journal of statistical software36 (2010), 1–13

    work page 2010

  35. [35]

    Jingjing Li et al. 2023. Prognostic role of E2F1 gene expression in human cancer: a meta-analysis.BMC cancer23, 1 (2023), 509

    work page 2023

  36. [36]

    Weiquan Li et al. 2022. M2-polarization-related CNTNAP1 gene might be a novel immunotherapeutic target and biomarker for clear cell renal cell carcinoma. IUBMB life74, 5 (2022), 391–407

    work page 2022

  37. [37]

    Yang Lu et al. 2007. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.Cancer research67, 17 (2007), 8240–8247

    work page 2007

  38. [38]

    Scott M Lundberg et al. 2020. From local explanations to global understanding with explainable AI for trees.Nature machine intelligence2, 1 (2020), 56–67

    work page 2020

  39. [39]

    Lundberg and Su-In Lee

    Scott M. Lundberg and Su-In Lee. 2017. A Unified Approach to Interpreting Model Predictions. InNIPS. 4765–4774

    work page 2017

  40. [40]

    Selma El Messaoudi-Aubert et al. 2010. Role for the MOV10 RNA helicase in polycomb-mediated repression of the INK4a tumor suppressor.Nature structural & molecular biology17, 7 (2010), 862–868

    work page 2010

  41. [41]

    Marija Milacic et al. 2024. The reactome pathway knowledgebase 2024.Nucleic acids research52, D1 (2024), D672–D678

    work page 2024

  42. [42]

    Patrick Mucka et al. 2023. CLK2 and CLK4 are regulators of DNA damage-induced NF-kB targeted by novel small molecule inhibitors.Cell Chemical Biology30, 10 (2023)

    work page 2023

  43. [43]

    Emilie Bousquet Mur et al . 2020. Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma.The Journal of Clinical Investigation130, 2 (2020), 612–624

    work page 2020

  44. [44]

    Harshini Muralidharan et al. 2024. Breast Cancer stem cells upregulate IRF6 in stromal fibroblasts to induce stromagenesis.Cells13, 17 (2024), 1466

    work page 2024

  45. [45]

    Marco Padilla-Rodriguez et al. 2018. The actin cytoskeletal architecture of estro- gen receptor positive breast cancer cells suppresses invasion.Nature communi- cations9, 1 (2018), 2980

    work page 2018

  46. [46]

    Simone Piaggesi et al. 2025. Explanations Go Linear: Post-Hoc Explainability for Tabular Data with Interpretable Meta-Encoding. InICDM. IEEE, 663–672

    work page 2025

  47. [47]

    Joseph A Pinto et al. 2017. In silico evaluation of DNA Damage Inducible Tran- script 4 gene (DDIT4) as prognostic biomarker in several malignancies.Scientific reports7, 1 (2017), 1526

    work page 2017

  48. [48]

    Yan Qin et al. 2022. GIMAP7 as a potential predictive marker for pan-cancer prognosis and immunotherapy efficacy.Journal of inflammation research(2022), 1047–1061

    work page 2022

  49. [49]

    Matthew G Rees et al . 2016. Correlating chemical sensitivity and basal gene expression reveals mechanism of action.Nature chemical biology12, 2 (2016), 109–116

    work page 2016

  50. [50]

    Why should i trust you?

    Marco Tulio Ribeiro et al. 2016. " Why should i trust you?" Explaining the pre- dictions of any classifier. InACM SIGKDD international conference on knowledge discovery and data mining. 1135–1144

    work page 2016

  51. [51]

    Rajat Rohatgi et al . 1999. The interaction between N-WASP and the Arp2/3 complex links Cdc42-dependent signals to actin assembly.Cell97, 2 (1999), 221–231

    work page 1999

  52. [52]

    Alejandro Roisman et al. 2023. B4galt1 Regulates the WNT-𝛽-Catenin Axis to Control Hematopoietic Stem and Progenitor Cells (HSPCs) Fitness.Blood142 (2023), 398

    work page 2023

  53. [53]

    Tetsuroh Saitoh et al. 2001. Molecular cloning and characterization of FRAT2, encoding a positive regulator of the WNT signaling pathway.Biochemical and Biophysical Research Communications281, 3 (2001), 815–820

    work page 2001

  54. [54]

    Bikash Ranjan Samal et al. 2022. Opportunities and challenges in interpretable deep learning for drug sensitivity prediction of cancer cells.Frontiers in Bioinfor- matics2 (2022), 1036963

    work page 2022

  55. [55]

    Haoyuan Shi et al . 2025. DRExplainer: Quantifiable interpretability in drug response prediction with directed graph convolutional network.Artificial Intelli- gence in Medicine163 (2025), 103101. Explainable AI for Cancer Drug Response Prediction: Beyond Univariate Feature Attributions KDD ’26, August 09–13, 2026, Jeju Island, Republic of Korea

    work page 2025

  56. [56]

    Jingwei Shi et al. 2022. Loss of interleukin-13-receptor-alpha-1 induces apoptosis and promotes EMT in pancreatic cancer.International Journal of Molecular Sciences23, 7 (2022), 3659

    work page 2022

  57. [57]

    Sabbir Ahmed Sibli et al . 2025. Enhancing protein structure predictions: DeepSHAP as a tool for understanding AlphaFold2.Expert Systems with Applica- tions(2025), 127853

    work page 2025

  58. [58]

    Hongbin Su et al. 2021. Ubiquitin-like protein UBD promotes cell proliferation in colorectal cancer by facilitating p53 degradation.Frontiers in oncology11 (2021), 691347

    work page 2021

  59. [59]

    Aravind Subramanian et al. 2005. Gene set enrichment analysis: a knowledge- based approach for interpreting genome-wide expression profiles.Proceedings of the National Academy of Sciences102, 43 (2005), 15545–15550

    work page 2005

  60. [60]

    Hyuna Sung et al. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA: a cancer journal for clinicians71, 3 (2021), 209–249

    work page 2021

  61. [61]

    Damian Szklarczyk et al. 2023. The STRING database in 2023: protein–protein association networks and functional enrichment analyses for any sequenced genome of interest.Nucleic acids research51, D1 (2023), D638–D646

    work page 2023

  62. [62]

    Yi-Ching Tang and Assaf Gottlieb. 2021. Explainable drug sensitivity prediction through cancer pathway enrichment.Scientific reports11, 1 (2021), 3128

    work page 2021

  63. [63]

    Christin Tse et al. 2008. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor.Cancer research68, 9 (2008), 3421–3428

    work page 2008

  64. [64]

    2011.Data mining and statistics for decision making

    Stéphane Tufféry. 2011.Data mining and statistics for decision making. John Wiley & Sons

    work page 2011

  65. [65]

    Mathias Uhlén et al. 2015. Tissue-based map of the human proteome.Science 347, 6220 (2015), 1260419

    work page 2015

  66. [66]

    Mian Xie et al. 2013. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.European journal of cancer49, 16 (2013), 3559–3572

    work page 2013

  67. [67]

    Li-Hao Yang et al. 2022. Neuronal survival factor VGF promotes chemoresis- tance and predicts poor prognosis in lung cancers with neuroendocrine feature. International Journal of Cancer151, 9 (2022), 1611–1625

    work page 2022

  68. [68]

    Jun Yin et al. 2019. let-7 and miR-17 promote self-renewal and drive gefitinib resistance in non-small cell lung cancer.Oncology Reports42, 2 (2019), 495–508

    work page 2019

  69. [69]

    Ming Yu et al. 2023. Elevated EVL methylation level in the normal colon mu- cosa is a potential risk biomarker for developing recurrent adenomas.Cancer Epidemiology, Biomarkers & Prevention32, 9 (2023), 1146–1152

    work page 2023

  70. [70]

    Qingbei Zeng et al. 2015. Discovery and evaluation of clinical candidate AZD3759, a potent, oral active, central nervous system-penetrant, epidermal growth factor receptor tyrosine kinase inhibitor.Journal of medicinal chemistry58, 20 (2015), 8200–8215

    work page 2015

  71. [71]

    Xiaoting Zhong et al. 2022. Explainable machine learning in materials science. npj computational materials8, 1 (2022), 204

    work page 2022

  72. [72]

    Jinfeng Zhu et al. 2022. FAT10 promotes chemotherapeutic resistance in pancre- atic cancer by inducing epithelial-mesenchymal transition via stabilization of FOXM1 expression.Cell death & disease13, 5 (2022), 497. APPENDIX A Data sources Transcriptomic data are derived from theCancer Cell Line Ency- clopedia(CCLE) [ 4], a collection of bulk RNA-seq data f...

    work page 2022